Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. Albert draws on his scientific, medical, and operating experience when working with his portfolio companies. He was an investor in Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals and Prestwick Pharmaceuticals. Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). He currently serves on the board of several private biopharmaceutical and medical device companies. Albert has also served as co-founder of several portfolio companies.
Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience. During his studies, he was elected to Alpha Omega Alpha and won the prestigious Outstanding Graduate Student Award. His research in molecular biophysics has been published in highly respected journals such as Nature and Neuron.
Dr. Cha is a member of the program committee for Dermatology Summit conferences from Advancing Innovation in Dermatology.
Dermatology is recognized as a burgeoning area with exciting innovation for patients, doctors, and investors.
Pascale Communications was on the scene at the annual American Academy of Dermatology (AAD).
DENVER — R. Rox Anderson, MD, professor of dermatology at Harvard Medical School and director of the Wellman Center for …